NCT02624180View on ClinicalTrials.gov

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 1, 2020

Study Completion Date

September 1, 2020

Conditions
Coronary Artery DiseaseHuman Immunodeficiency Virus
Interventions
DRUG

Colchicine

Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.

DRUG

Placebo

A substance containing no medication

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Johns Hopkins University

OTHER

NCT02624180 - Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV | Biotech Hunter | Biotech Hunter